KalVista Pharmaceuticals (STU:4XC1) Total Operating Expense : €113.84 Mil (TTM As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Total Operating Expense?

KalVista Pharmaceuticals's Total Operating Expense for the three months ended in Jan. 2024 was €30.43 Mil. KalVista Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Jan. 2024 was €113.84 Mil.

KalVista Pharmaceuticals Total Operating Expense Historical Data

The historical data trend for KalVista Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Total Operating Expense Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Total Operating Expense

Get a 7-Day Free Trial

40.89

48.97

48.42

89.46

101.11

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Operating Expense	Get a 7-Day Free Trial															25.01	28.94	26.30	28.17	30.43

KalVista Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €113.84 Mil.

KalVista Pharmaceuticals Total Operating Expense Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines